转移性结直肠癌抗EGFR治疗耐药机制研究进展

Review of research progress on mechanism of resistance to anti-EGFR therapy in metastatic colorectal cancer

转移性结直肠癌(mCRC)是结直肠癌进展的晚期阶段,治疗选择多样,但患者预后通常不佳。表皮生长因子受体(EGFR)信号通路在mCRC的发展中扮演核心角色,涉及多个关键分子。EGFR异常活化与肿瘤生长、转移及治疗耐药紧密相关。因此,EGFR靶向治疗对mCRC至关重要,但治疗耐药常常导致治疗失败,且分子机制复杂。在此,笔者综述mCRC抗EGFR治疗耐药的相关分子机制及干预研究进展,为深入理解抗EGFR耐药机制,优化治疗策略提供参考。

Metastatic colorectal cancer(mCRC)represents the advanced stage of colorectal cancer progression.Treatment options are diverse,but patient prognosis is generally poor.The epidermal growth factor receptor(EGFR)signaling pathway plays a central role in the development of mCRC,involving multiple key molecules.Abnormal activation of EGFR is closely related to tumor growth,metastasis,and treatment resistance.Therefore,EGFR-targeted therapy is crucial for mCRC,but treatment resistance often leads to therapy failure,and the molecular mechanisms are complex.Here,the authors review the molecular mechanisms related to anti-EGFR treatment resistance in mCRC and the progress in intervention studies,providing a reference for a deeper understanding of the mechanisms of anti-EGFR resistance and the optimization of treatment strategies.